Schedule H1 Drug Register Compliance Guide (India)

the most inspected document in your pharmacy is probably your weakest

There's a specific moment during a Drug Inspector visit — usually about ten minutes in, after the credentials are shown and the license on the wall gets a glance — when the inspector says some version of "can I see your Schedule H1 register?" This is the moment that determines how the next hour goes.

The H1 register exists because of a 2013 amendment to the Drugs and Cosmetics Rules that created Schedule H1 in the first place. The logic was sound: certain antibiotics, anti-TB drugs, and habit-forming substances were being sold across the counter without prescriptions, contributing to antimicrobial resistance that is, by any measure, a genuine public health crisis. The register creates an audit trail proving that every sale of an H1 drug was backed by a valid prescription from a licensed doctor.

Every pharmacy that sells H1 drugs is supposed to maintain this register. Most do. Most also have gaps in it that they're not aware of until the inspector starts reading line by line, cross-referencing against the billing records, and asking questions. The problem is not that pharmacy owners don't care about compliance — it's that between billing 200 customers a day, managing staff, receiving deliveries, handling distributor payments, and running an actual business, the register gets filled imperfectly. And "imperfectly" is where inspectors find their leverage.

what Rule 65(15A) actually requires

Every sale of a Schedule H1 drug must be recorded with: the name of the drug (brand name and generic name — both, not either), the quantity sold, the batch number of the specific strip or bottle, the patient's name and address, the prescribing doctor's name and registration number (State Medical Council or MCI number), and the date of sale. Records must be retained for a minimum of three years from the date of the last entry. The register can be physical or digital, but digital must be tamper-proof and printable on demand.

That last requirement — tamper-proof — trips up more pharmacies than any other single point. "Tamper-proof" means the system must prevent retroactive editing of entries without maintaining an audit trail. Most pharmacy billing software has an "edit sale" function that lets you go back and modify a completed transaction. If your H1 register lives inside a system that allows this without logging the original entry, the amendment, and who made it, an inspector may not accept it as compliant. The register is a legal document. Legal documents don't get quietly corrected after the fact.

seven gaps that generate notices

I'll describe these in roughly the order of how frequently they appear in enforcement actions, starting with the most common.

Missing batch numbers. The register has a column for batch number. Most pharmacies leave it blank. The billing system doesn't require it at point of sale — the staff member remembers the drug name, selects it from the dropdown, enters the quantity, and moves on. No scan, no batch lookup. The batch number column sits empty. Without it, the entry is unverifiable. If a recall is issued for a specific batch, you cannot determine which patients received that batch. Inspectors identify this gap instantly because all they have to do is scan one column. It's either filled or it isn't.

Brand name without generic name. Recording "Augmentin 625" satisfies nobody at the regulatory level. The register requires the generic composition: Amoxicillin 500mg + Potassium Clavulanate 125mg. Inspectors use generic names to identify prescribing patterns, detect potential misuse, and cross-reference with scheduled substance categories. Brand names alone don't provide this information, and the register format was designed with generic names as a mandatory field for precisely this reason.

No doctor registration number. "Dr. Sharma" is not sufficient identification. The registration number — State Medical Council or MCI — allows inspectors to verify that the prescriber is a licensed practitioner and to cross-reference prescribing patterns across pharmacies. Without it, the sale is technically undocumented from a compliance perspective even if the prescription itself was genuine. This matters particularly because one of the things H1 enforcement is designed to detect is prescriptions from unlicensed practitioners.

End-of-day backfilling. This is the most common practice in Indian pharmacies and also the most recognisable to inspectors. The day gets busy. Nobody fills the register at the point of sale. At closing time, someone sits with the billing records and fills in the register retroactively. Inspectors know what this looks like: every entry carries the same timestamp (all sales apparently occurring at "6:00 PM"), the handwriting is too uniform (one person, one sitting, rather than the natural variation of multiple staff throughout the day), and there are entries missing for sales that appear in the POS but not in the register. They compare the two documents. Discrepancies — sales logged in the billing system with no corresponding register entry — indicate either unregistered H1 sales or retrospective record-keeping. Neither interpretation helps you.

Free samples not recorded. Physician samples and promotional stock of H1 drugs that pass through the pharmacy's inventory and leave the premises are subject to register requirements. The rationale is straightforward: if a scheduled substance entered your custody and left it, there must be a record of where it went. Many pharmacies treat samples as outside the register's scope because no sale occurred. The regulation disagrees.

Physical register condition. Torn pages. Correction fluid. Entries in pencil. Overwritten numbers. Each of these is a red flag. The register is a legal document, and legal documents have specific correction protocols: strike through with a single line, initial beside the correction, write the correct entry alongside. Correction fluid makes the original entry unreadable, which inspectors treat as potential evidence tampering regardless of intent. A register that looks like it's been maintained carefully communicates competence. One that looks like a rough draft communicates the opposite.

No link between expired stock and destruction records. When H1 drugs expire, the destruction process requires Form 29 documentation. The register should show the batch that was stocked; Form 29 should reference the same batch being destroyed. If the batch number is missing from the register (see gap number one), this linkage is impossible. If Form 29 exists but references a batch not found in the register, that's a different kind of gap — one that raises questions about where those drugs came from. The paperwork needs to form a closed loop: purchase → register → sale or destruction. Breaks in the loop invite scrutiny.

what the inspection looks like, minute by minute

The first ten minutes are visual. The inspector checks the license display, looks at storage conditions, verifies that Schedule H and H1 drugs are stored in a labelled, separate section. This is routine and most pharmacies pass without issue.

The next fifteen to twenty minutes is the register. This is the inspection within the inspection. The typical approach: select five to ten random entries and verify every column is complete. Pick two or three entries and cross-reference them against the billing system — does the sale appear in both places? Does the batch number match? Review the last thirty days for consistency in timing, handwriting, and completeness. Scan the batch number column for blanks.

After the register, there may be cold chain record checks (if you stock temperature-sensitive drugs), random shelf pulls to check for expired stock, and controlled substance register reviews if applicable. But the H1 register absorbs the bulk of the inspection time and attention. It's the document most likely to reveal gaps, because it requires the most discipline to maintain correctly and involves the highest volume of entries.

The response to findings scales predictably. Verbal warning for minor, first-time issues. Written observation with a correction timeline for more significant gaps. Show-cause notice under Rule 65 for patterns of non-compliance. Prosecution recommendation for egregious or repeated violations. Missing batch numbers on two entries out of fifty might get a verbal warning. A register that's been empty for three months while the POS shows active H1 sales triggers a fundamentally different response.

CDSCO is going digital, and that changes the calculation

The DAVA portal, state-level digital drug tracking initiatives, and CDSCO's broader digital agenda all point in one direction: electronic records that are searchable, auditable, and linked to supply chain data. A fully digital H1 register isn't universally mandated yet, but the trajectory is unmistakable. Pharmacies that adopt digital register-keeping now will have the transition behind them when it becomes mandatory. Pharmacies that wait will be converting under pressure, which is always more expensive and more error-prone than converting at a time of your choosing.

The requirements for an acceptable digital register: tamper-proof entries (no editing without an audit trail that preserves the original), printable on demand in register format (not in Excel export format — in register format, as an inspector expects to see it), batch-level linking between the sale entry and the inventory record, and ideally prescription image storage. Storing a photograph of the physical prescription alongside the digital register entry creates the strongest possible compliance evidence, because it closes the evidentiary chain: the prescription exists, the sale was recorded, and the two are linked.

what it costs to get this right versus what it costs to get it wrong

A bound physical register: ₹200-500. A digital system with H1 register capability: ₹0 if your existing POS supports it, ₹5,000-15,000 per year for pharmacy-specific software that includes this function. Staff time for proper documentation at 20 H1 sales per day, at 2-3 minutes per sale: 40-60 minutes daily, which at pharmacy helper wages works out to roughly ₹1.2 lakhs per year.

On the other side of the ledger: legal consultation fees for responding to a show-cause notice run ₹5,000-15,000. Penalties under Rule 65 can reach ₹1 lakh for a first offence. A license suspension costs you ₹20,000-50,000 per day in lost revenue. License cancellation costs you the business.

There is no scenario in which the documentation cost exceeds the non-compliance cost. Not even close. The only rational objection to maintaining the register properly is "I don't have time," and the answer to that objection is that three minutes per H1 sale is the cost of being allowed to sell H1 drugs at all.

the drugs on the list

Approximately 46 drugs and combinations, primarily antibiotics (Cefixime, Azithromycin, Ofloxacin, Ciprofloxacin, and several other fluoroquinolones and cephalosporins), anti-TB drugs (Rifampicin, Isoniazid, Ethambutol, Pyrazinamide when sold individually rather than as fixed-dose combinations), anti-malarials (Artesunate combinations), and a small number of others including low-dose Alprazolam formulations and codeine-containing cough syrups. The list is updated through Gazette notifications. Check it annually.

ShelfLifePro generates a compliant H1 register from every sale automatically — batch number, generic name, doctor details, prescription linking. No separate register to maintain. No end-of-day backfilling. The record exists because the sale happened.